IN2012DN02764A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02764A
IN2012DN02764A IN2764DEN2012A IN2012DN02764A IN 2012DN02764 A IN2012DN02764 A IN 2012DN02764A IN 2764DEN2012 A IN2764DEN2012 A IN 2764DEN2012A IN 2012DN02764 A IN2012DN02764 A IN 2012DN02764A
Authority
IN
India
Prior art keywords
subject
reduce
thi
fragments
inhibit
Prior art date
Application number
Other languages
English (en)
Inventor
Langermann Solomon
Liu Linda
Original Assignee
Amplimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amplimmune Inc filed Critical Amplimmune Inc
Publication of IN2012DN02764A publication Critical patent/IN2012DN02764A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
IN2764DEN2012 2009-08-31 2010-08-31 IN2012DN02764A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US23860509P 2009-08-31 2009-08-31
US25493009P 2009-10-26 2009-10-26
US26685409P 2009-12-04 2009-12-04
US28653709P 2009-12-15 2009-12-15
US37836110P 2010-08-30 2010-08-30
PCT/US2010/047384 WO2011026132A2 (fr) 2009-08-31 2010-08-31 Méthodes et compositions permettant d'inhiber les rejets de greffe

Publications (1)

Publication Number Publication Date
IN2012DN02764A true IN2012DN02764A (fr) 2015-09-18

Family

ID=42990231

Family Applications (2)

Application Number Title Priority Date Filing Date
IN2764DEN2012 IN2012DN02764A (fr) 2009-08-31 2010-08-31
IN2753DEN2012 IN2012DN02753A (fr) 2009-08-31 2010-08-31

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN2753DEN2012 IN2012DN02753A (fr) 2009-08-31 2010-08-31

Country Status (8)

Country Link
US (4) US9005616B2 (fr)
EP (2) EP2473523A2 (fr)
JP (2) JP2013503204A (fr)
CN (2) CN102666581A (fr)
AU (2) AU2010286351A1 (fr)
CA (2) CA2772204A1 (fr)
IN (2) IN2012DN02764A (fr)
WO (2) WO2011026132A2 (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010187A1 (fr) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 et b7-h4, nouvelles molecules immunoregulatrices
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
EP2586458B1 (fr) * 2006-12-27 2016-08-24 The Johns Hopkins University Compositions et procédés pour le traitement d'inflammations et de maladies auto-immunes
EP2473523A2 (fr) * 2009-08-31 2012-07-11 Amplimmune, Inc. Méthodes et compositions permettant d'inhiber les rejets de greffe
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US8563558B2 (en) * 2010-12-06 2013-10-22 Confluence Life Sciences, Inc. Substituted pyridine urea compounds
WO2012145568A1 (fr) * 2011-04-21 2012-10-26 Albert Einstein College Of Medicine Of Yeshiva University Anticorps contre b7x humain pour le traitement du cancer métastatique
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
AU2013361275B2 (en) * 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP2997373A1 (fr) 2013-05-17 2016-03-23 MedImmune, LLC Récepteurs pour b7-h4
WO2014194293A1 (fr) 2013-05-30 2014-12-04 Amplimmune, Inc. Méthodes améliorées de sélection de patients pouvant être soumis à des thérapies ciblant pd-1 ou b7-h4, et polythérapies associées
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
US10370776B2 (en) * 2013-09-25 2019-08-06 Idea Orchard, Llc Antibody like protein
TW202228700A (zh) * 2013-12-02 2022-08-01 美商製藥公司 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
WO2015094782A1 (fr) * 2013-12-18 2015-06-25 Albert Einstein College Of Medicine Of Yeshiva University B7x et ses dérivés pour le traitement et la prévention de maladies cardiovasculaires
CA2946064C (fr) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Agents therapeutiques de glycociblage
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
BR112016020987B1 (pt) 2014-03-12 2023-11-14 Western Sydney Local Health District Método de identificação de receptores de aloenxerto renal e método de seleção de receptor do aloenxerto renal
US9730988B2 (en) * 2014-04-10 2017-08-15 University Of Iowa Research Foundation Parasitic biological agents for treatment and prevention of graft versus host disease
ES2850281T3 (es) 2014-06-26 2021-08-26 Icahn School Med Mount Sinai Método para diagnosticar el rechazo agudo subclínico y clínico mediante el análisis de conjuntos de genes predictivos, un agente terapéutico para usar en el tratamiento y kits para determinar la expresión
AU2015279621B2 (en) 2014-06-26 2021-04-08 Icahn School Of Medicine At Mount Sinai Methods for diagnosing risk of renal allograft fibrosis and rejection
WO2016146143A1 (fr) 2015-03-16 2016-09-22 Amal Therapeutics Sa Peptides pénétrant dans les cellules et complexes comprenant ceux-ci
WO2016177682A1 (fr) 2015-05-06 2016-11-10 Snipr Technologies Limited Altération de populations microbiennes et modification de microbiote
CN108351687B (zh) 2015-09-04 2022-01-07 耶鲁大学 靶向胰腺和结肠的聚合胆汁酸纳米组合物
USRE50535E1 (en) 2015-09-17 2025-08-19 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions comprising pregnancy specific glycoproteins and methods of use thereof
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
EP3429618B1 (fr) 2016-03-16 2024-02-21 Amal Therapeutics SA Association d'un modulateur de points de contrôle immunologiques et d'un complexe comprenant un peptide de pénétration cellulaire, un cargo et un agoniste des peptides tlr pour une utilisation en médecine
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3263595A1 (fr) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Protéine de fusion pour une utilisation dans le traitement de maladie hvg
KR102644544B1 (ko) 2016-09-21 2024-03-11 넥스트큐어 인코포레이티드 Siglec-15를 위한 항체 및 이의 사용 방법
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
EP4360714A3 (fr) 2016-09-21 2024-07-24 Nextcure, Inc. Anticorps pour siglec-15 et leurs procédés d'utilisation
EP3518946A4 (fr) 2016-09-27 2020-09-09 Board of Regents, The University of Texas System Procédés permettant d'améliorer le traitement par blocage du point de contrôle immunitaire en modulant le microbiome
WO2018071668A1 (fr) 2016-10-12 2018-04-19 Board Of Regents, The University Of Texas System Procédés et compositions pour une immunothérapie par tusc2
WO2018099539A1 (fr) 2016-11-29 2018-06-07 Horst Lindhofer Combinaison d'anticorps multifonctionnels de redirection de lymphocytes (t) avec des modulateurs de point de contrôle immunitaires et leurs utilisations
WO2018111902A1 (fr) 2016-12-12 2018-06-21 Multivir Inc. Méthodes et compositions comprenant une thérapie génique virale et un inhibiteur de point de contrôle immunitaire pour le traitement et la prévention du cancer et des maladies infectieuses
US20200181225A1 (en) * 2017-03-29 2020-06-11 Sunnybrook Research Institute Engineered t-cell modulating molecules and methods of using same
CN118892540A (zh) 2017-04-21 2024-11-05 新罗杰股份有限公司 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法
CA3064333A1 (fr) 2017-05-29 2018-12-06 Gamamabs Pharma Inhibiteur d'immunosuppression associe au cancer
EP3638296A1 (fr) 2017-06-16 2020-04-22 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
WO2018237003A1 (fr) * 2017-06-23 2018-12-27 Sanford Health Procédés de production de cellules t régulatrices induites
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
AU2018338786A1 (en) * 2017-09-29 2020-04-16 Nantcell, Inc. Antigenic proteins and methods therefor
CN112566934B (zh) 2018-01-23 2024-09-17 奈斯科尔公司 B7-h4抗体及其使用方法
CN108236719A (zh) * 2018-01-29 2018-07-03 中山大学附属第三医院（中山大学肝脏病医院） B7-h4融合蛋白在制备治疗系统性红斑狼疮药物中的用途
WO2019165077A1 (fr) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. Formulations d'anticorps b7-h4
US12090142B2 (en) 2018-02-22 2024-09-17 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
CA3094329A1 (fr) 2018-03-19 2020-02-20 Multivir Inc. Procedes et compositions comprenant une therapie genique suppressive de tumeur et des agonistes de cd122/cd132 pour le traitement du cancer
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CA3094458A1 (fr) 2018-03-25 2019-10-31 Snipr Biome Aps. Traitement et prevention des infections microbiennes
JP7464279B2 (ja) 2018-04-16 2024-04-09 アイカーン スクール オブ メディスン アット マウント シナイ レシピエント血液における移植前トランスクリプトームシグネチャーを使用した急性拒絶反応および腎臓同種異系移植喪失の予測のための方法およびキット
EP3790577A4 (fr) 2018-05-09 2022-04-27 The University of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
AU2019361923B2 (en) 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
CN109439626B (zh) * 2018-11-09 2022-10-14 复旦大学附属中山医院 一种有助于体外获得Th22细胞的组合物及其用途
CA3120576A1 (fr) 2018-11-26 2020-06-04 Massachusetts Institute Of Technology Compositions et procedes pour induire une tolerance immunitaire
WO2021024020A1 (fr) 2019-08-06 2021-02-11 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer
WO2021113644A1 (fr) 2019-12-05 2021-06-10 Multivir Inc. Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer
WO2021245071A1 (fr) 2020-06-03 2021-12-09 Mv Biotherapeutics Sa Combinaison d'une enzyme hydrolysant l'atp et d'un modulateur de point de contrôle immunitaire et ses utilisations
JP2023532204A (ja) 2020-06-19 2023-07-27 イェール ユニバーシティー 抗原特異的寛容を誘導する免疫調節剤を含むポリマー胆汁酸エステルナノ粒子
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
CN114426974B (zh) * 2020-10-29 2023-11-21 洛阳普泰生物技术有限公司 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段
WO2022135666A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Programme de traitement faisant intervenir des protéines cytokines
WO2022135667A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Arn thérapeutique pour le traitement du cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2023285552A1 (fr) 2021-07-13 2023-01-19 BioNTech SE Agents de liaison multispécifiques contre cd40 et cd137 en polythérapie du cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
CN117586418B (zh) * 2023-11-08 2025-07-15 东南大学 一种丝氨酸蛋白酶抑制剂及其应用
WO2025120866A1 (fr) 2023-12-08 2025-06-12 Astellas Pharma Inc. Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et agents stabilisant ou augmentant l'expression de cldn18.2
WO2025120867A1 (fr) 2023-12-08 2025-06-12 Astellas Pharma Inc. Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et anticorps anti-vegfr2
WO2026033885A1 (fr) 2024-08-08 2026-02-12 Astellas Pharma Inc. Polythérapie faisant intervenir des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et agents stabilisant ou augmentant l'expression de cldn18.2
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
CN121041407B (zh) * 2025-11-04 2026-03-17 深圳市沃英达生命科学有限公司 降低干细胞移植排斥的组合物及应用

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1339281A (en) 1920-01-26 1920-05-04 Stearns Upholstery-fold
GB1268212A (en) 1968-04-19 1972-03-22 Zaidan Hojin Biseibutsu Tripeptide derivatives
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5155020A (en) 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US6808901B1 (en) 1984-09-03 2004-10-26 Celltech R&D Limited Production of chimeric antibodies
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0279582A3 (fr) 1987-02-17 1989-10-18 Pharming B.V. Séquences d'ADN pour diriger des protéines vers les glandes mammaires afin d'être sécrétées efficacement
US4853871A (en) 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5750666A (en) 1988-05-26 1998-05-12 Competitve Technologies, Inc. Polynucleotide phosphorodithioate compounds
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5175099A (en) 1989-05-17 1992-12-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5204243A (en) 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992005186A1 (fr) 1990-09-20 1992-04-02 Gilead Sciences Liaisons internucleosides modifiees
US5296347A (en) 1991-02-08 1994-03-22 Ciba Corning Diagnostics Corp. Bridge immunoassay
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
WO1993001222A1 (fr) 1991-07-03 1993-01-21 Kanebo, Ltd. Elastomere de polyurethane thermoplastique, procede et dispositif de production, et fibre elastique realisee a partir de cet elastomere
US5202332A (en) 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0633783B1 (fr) 1992-03-30 2000-06-07 American Home Products Corporation Formulation de rapamycine pour injections intraveineuses
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5387680A (en) 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
BR9408323A (pt) 1993-12-17 1997-08-19 Sandoz Ag Derivados de rapamicina
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5362735A (en) 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
NZ322175A (en) 1995-11-10 1999-02-25 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying the same
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6982323B1 (en) 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
IL139686A0 (en) 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1082417A4 (fr) 1998-06-04 2006-08-23 Univ Queensland Sequences genetiques modifiant le phenotype
GB9814640D0 (en) 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
US6015809A (en) 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
ATE413466T1 (de) 1998-09-02 2008-11-15 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2377513A1 (fr) 1999-06-25 2001-01-04 Universitat Zurich Peptides bispirales a hetero-association
AU6058500A (en) 1999-06-30 2001-01-31 Center For Blood Research, The Fusion protein and uses thereof
DE19937656A1 (de) 1999-08-13 2001-02-15 Aventis Behring Gmbh Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen
EP1301524A1 (fr) * 2000-06-30 2003-04-16 Human Genome Sciences, Inc. Polynucl otides du type b7, polypeptides et anticorps en rapport
AU2001273194A1 (en) 2000-06-30 2002-01-14 Amgen Inc. B7-Like Molecules and Uses Thereof
US6537968B1 (en) 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
WO2002010187A1 (fr) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 et b7-h4, nouvelles molecules immunoregulatrices
US6551786B2 (en) 2001-01-04 2003-04-22 Myriad Genetics, Inc. Screen assay for selecting protein-protein interaction modulators
JP4454934B2 (ja) 2001-01-26 2010-04-21 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 組換えクローニングを用いて効率のよいサイレンシング構築物を作製する方法および手段
WO2002066058A1 (fr) 2001-02-19 2002-08-29 Merck Patent Gmbh Anticorps anti-egfr modifies presentant une immunogenicite reduite
EP1539218A4 (fr) 2002-06-20 2007-08-22 Univ California Compositions et procedes de modulation de l'activite lymphocytaire
US20040152105A1 (en) 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
US7449300B2 (en) 2002-11-21 2008-11-11 Mayo Foundation For Medical Education And Research Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
US7534423B2 (en) 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual
US20050163772A1 (en) 2003-06-16 2005-07-28 University Of Washington B7S1: an immune modulator
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
WO2006101487A1 (fr) 2005-03-18 2006-09-28 The Board Of Trustees Of The Leland Stanford Junior University Production et usages therapéutiques de cellules t regulatoires de type th1
EP3683230A1 (fr) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions et procédés pour moduler les réponses immunologiques
DK1907000T4 (da) 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
SG10202001007TA (en) * 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
EP1973572A2 (fr) * 2005-12-08 2008-10-01 University of Louisville Research Foundation, Inc. Modification in vivo de surfaces cellulaires
US8241621B2 (en) 2006-12-18 2012-08-14 Medistem Laboratories Stem cell mediated treg activation/expansion for therapeutic immune modulation
EP2586458B1 (fr) 2006-12-27 2016-08-24 The Johns Hopkins University Compositions et procédés pour le traitement d'inflammations et de maladies auto-immunes
US20090142342A1 (en) 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
CA2678180A1 (fr) 2007-02-13 2008-12-04 Northeastern University Procedes et compositions pour ameliorer les reponses immunitaires
US20100203035A1 (en) 2007-02-14 2010-08-12 Kwon Eugene D B7-h3 in cancer
WO2008138017A2 (fr) * 2007-05-08 2008-11-13 Beth Israel Deaconess Medical Center, Inc. Procédés et compositions permettant de modifier des réponses immunitaires de lymphocyte t et l'inflammation
SI2162011T1 (sl) 2007-07-02 2011-05-31 Sime Darby Malaysia Berhad Mešanica rastlinskih maščob in jedilni proizvodi, ki vsebujejo takšno mešanico maščob
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
CA2711696C (fr) 2008-01-09 2021-10-26 Reza Dana Compositions therapeutiques utilisees pour le traitement des affections inflammatoires oculaires
EP2473523A2 (fr) 2009-08-31 2012-07-11 Amplimmune, Inc. Méthodes et compositions permettant d'inhiber les rejets de greffe
JP2012118516A (ja) 2010-11-11 2012-06-21 Konica Minolta Business Technologies Inc ホログラム画像形成方法、静電荷像現像用トナーおよびホログラム画像形成装置
EP2997373A1 (fr) * 2013-05-17 2016-03-23 MedImmune, LLC Récepteurs pour b7-h4

Also Published As

Publication number Publication date
WO2011026122A3 (fr) 2011-04-28
US20160039905A1 (en) 2016-02-11
US20160039906A1 (en) 2016-02-11
IN2012DN02753A (fr) 2015-09-18
US9011853B2 (en) 2015-04-21
WO2011026132A3 (fr) 2011-04-21
CA2772199A1 (fr) 2011-03-03
US20120177645A1 (en) 2012-07-12
EP2473521A2 (fr) 2012-07-11
AU2010286361A1 (en) 2012-03-15
JP2013503204A (ja) 2013-01-31
AU2010286351A1 (en) 2012-03-15
WO2011026132A2 (fr) 2011-03-03
WO2011026132A8 (fr) 2011-11-03
EP2473523A2 (fr) 2012-07-11
JP2013503205A (ja) 2013-01-31
CN102741279A (zh) 2012-10-17
CA2772204A1 (fr) 2011-03-03
US20120276095A1 (en) 2012-11-01
US9005616B2 (en) 2015-04-14
US9957312B2 (en) 2018-05-01
CN102666581A (zh) 2012-09-12
WO2011026122A2 (fr) 2011-03-03

Similar Documents

Publication Publication Date Title
WO2011026132A3 (fr) Méthodes et compositions permettant d'inhiber les rejets de greffe
TW200740998A (en) Use of adipose tissue-derived stromal cells in spinal fusion
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
WO2012019168A3 (fr) Acides nucléiques modifiés et leurs procédés d'utilisation
WO2014186469A3 (fr) Application à des humains de lymphocytes t comprenant un récepteur antigénique chimérique (car)
SG10201805411YA (en) Chimeric antigen receptors
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
NZ630469A (en) Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
SG10201806648TA (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
MX359551B (es) Agentes de union diana contra b7-h1.
ATE523585T1 (de) Differenzierung menschlicher embryonaler stammzellen
MX2009013706A (es) Celulas multipotentes/pluripotentes y metodos relacionados.
WO2012006426A3 (fr) Polynucléotides régulateurs et leurs utilisations
WO2011084808A3 (fr) Compositions de polypeptides bifonctionnels et procédés pour le traitement de maladies métaboliques et cardiovasculaires
IN2012DN02981A (fr)
MY176922A (en) Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
CA2801009C (fr) Cellules souches issues de la gelee de wharton natives et leur purification
MY184241A (en) Human antibodies to gfr?3 and methods of use thereof
PH12012502406A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2011043629A3 (fr) Procédé d'induction d'une activité élevée des cellules souches adipeuses humaines et milieu associé
WO2007116404A3 (fr) Glucosides de cucurbitacine et leur utilisaton dans le traitment du cancer
NZ710900A (en) Il-1β inhibitor composition and use thereof
NZ610620A (en) Inhibitors of apoptosis and uses thereof
WO2012048170A3 (fr) Animaux humanisés par ingénierie tissulaire et leurs utilisations